MIVAZEROL HYDROCHLORIDE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C11H11N3O2.ClH
Molecular Weight	253.685
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

Cl.NC(=O)C1=C(O)C(CC2=CNC=N2)=CC=C1

InChI

InChIKey=YJJUPMPFHKRGKP-UHFFFAOYSA-N

InChI=1S/C11H11N3O2.ClH/c12-11(16)9-3-1-2-7(10(9)15)4-8-5-13-6-14-8;/h1-3,5-6,15H,4H2,(H2,12,16)(H,13,14);1H

HIDE SMILES / InChI

Molecular Formula	ClH
Molecular Weight	36.461
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C11H11N3O2
Molecular Weight	217.2239
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9241327 | https://www.ncbi.nlm.nih.gov/pubmed/8764590 | https://www.ncbi.nlm.nih.gov/pubmed/18494845

Mivazerol is a new and selective alpha 2-adrenoceptor agonist, devoid of hypotensive effects, which has been designed to prevent adverse cardiac outcome in perioperative patients with, or at risk coronary artery disease. This compound, which lacks hypotensive effects, has been demonstrated to prevent hyperadrenergic activity and myocardial ischemia in perioperative patients and tachycardia in rats at emergence from halothane anesthesia. This type of ischemia, frequently encountered in postoperative patients, is considered to be a consequence of stress-induced hyperactivation of the sympathetic system. Anti-ischemic effects of this compound have been demonstrated in different animal models of myocardial ischemia, and Mivazerol has also been shown to improve exercise-induced ischemia in patients with angina pectoris.

Originator

Approval Year

PubMed

Title	Date	PubMed
Mivazerol prevents the tachycardia caused by emergence from halothane anesthesia partly through activation of spinal alpha 2-adrenoceptors.	1998 Feb	9509210
[Efficacy of oncologic surgery. Does anesthesia influence the postoperative outcome?].	2001 Apr	11370395
Alpha-2 adrenergic agonists to prevent perioperative cardiovascular complications: a meta-analysis.	2003 Jun 15	12829201
Pharmacologic myocardial protection in patients undergoing noncardiac surgery: a quantitative systematic review.	2003 Sep	12933373
[Clonidine and anesthesia].	2004 Mar	15382458
Neuroprotective effect of mivazerol, an alpha 2-agonist, after transient forebrain ischemia in rats.	2005 Sep	16095453
Perioperative use of alpha2-adrenoceptor agonists and the cardiac patient.	2006 May	16507202
Effect of mivazerol, a alpha-agonist, on striatal norepinephrine concentration during transient forebrain ischemia in rats.	2008 Aug	18494845
Effects of neuraxial blockade may be difficult to study using large randomized controlled trials: the PeriOperative Epidural Trial (POET) Pilot Study.	2009	19247497
Alpha2-adrenergic agonists and their role in the prevention of perioperative adverse cardiac events.	2009 Apr	19388504
Hypothermic responses to infection are inhibited by alpha2-adrenoceptor agonists with possible clinical implications.	2009 Oct	19628485
Alpha-2 adrenergic agonists for the prevention of cardiac complications among patients undergoing surgery.	2009 Oct 7	19821319

Patents

Substance Class	Chemical Created by `admin` on `Fri Dec 15 15:40:46 GMT 2023` Edited by `admin` on `Fri Dec 15 15:40:46 GMT 2023`
Record UNII	26T3OU6NN2
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

MIVAZEROL HYDROCHLORIDE

Common Name

English

MIVAZEROL HYDROCHLORIDE [MI]

Common Name

English

3-((1H-IMIDAZOL-4-YL)METHYL)-2-HYDROXYBENZAMIDE HYDROCHLORIDE

Systematic Name

English

UCB-22073

Common Name

English

Code System Code Type Description

EPA CompTox

DTXSID00155448